MetaCap

Kyverna Therapeutics (KYTX) vs SAB Biotherapeutics (SABS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

SAB Biotherapeutics (SABS) has outperformed Kyverna Therapeutics (KYTX) over the past year, losing 28.9% versus a loss of 39.9%. Kyverna Therapeutics is the larger company by market cap ($269.3 million vs $253.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KYTX-39.92%SABS-28.86%
+64%+9%-45%
Nov 21, 20251 yearNov 20, 2026
KYTX-85.85%SABS-52.93%
+5%-47%-99%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KYTX versus SABS key metrics
MetricKYTXSABS
Share price$4.26$2.81
Market cap$269.33M$253.15M
1-day change-2.52%-3.44%
YTD return-54.68%-24.87%
1-year return-39.92%-28.86%
5-year return—-97.32%
EPS (TTM)$-2.75$-1.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-161.31M$13.27M
52-week high$13.67$5.15
52-week low$4.18$2.44
Distance from 52-week high-68.84%-45.44%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+613.62%+314.23%
Average volume867.28K633.60K
Shares outstanding63.22M90.09M
Employees17286
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SABS has outperformed KYTX by 11.1 percentage points over the past year.

About Kyverna Therapeutics

KYTX stock →

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 172 employees

About SAB Biotherapeutics

SABS stock →

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees

KYTX vs SABS FAQ

Which is bigger, Kyverna Therapeutics or SAB Biotherapeutics?

Kyverna Therapeutics (KYTX) is larger, with a market capitalization of $269.33M compared with $253.15M for SAB Biotherapeutics (SABS).

Which stock has performed better over the past year, KYTX or SABS?

SABS returned -28.86% over the past 12 months, compared with -39.92% for KYTX (price return, excluding dividends). Past performance does not predict future results.

Are Kyverna Therapeutics and SAB Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons